[CD56⁺急性髓系白血病患者的免疫表型分析]

[Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia].

作者信息

Guo Rui, Shen An-Li, Wang Yan, Liu Lu, Zhang Jian-Fu, Wang Rong, Li Jian-Yong, Wu Yu-Jie

机构信息

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China. E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1231-4. doi: 10.7534/j.issn.1009-2137.2015.05.002.

DOI:10.7534/j.issn.1009-2137.2015.05.002

PMID:26524014

Abstract

OBJECTIVE

To explore the immunophenotype characteristics of newly diagnosed patients with CD56⁺ acute myeloid leukemia (AML).

METHODS

Combining with cytomorphology, four-color flow cytometry was used to analyze the immunophenotype of 342 AML patients with CD56⁺ or CD56⁻.

RESULTS

In 342 AML patients, the CD56⁺ expression was found in 83 AML patients who accounted for 24.27% and included 10 cases of M1, 45 cases of M2, 5 cases of M3, 6 cases of M6 and 17 cases of M5. The statistical analysis showed that there was statistical difference between CD56⁺ and CD11b⁺ patients (P < 0.05), but there was no statistical difference between CD56⁺ and HLA-DR, CD34, CD38, CD13, CD33, CD15, CD117, CD14, CD64, CD2, CD7, CD5, CD3, CD4, CD10, CD19, CD20, CD22 (P > 0.05).

CONCLUSION

AML with only CD56 positive always has poor prognosis, thus the prognosis of patients with CD56⁺ AML accompanied by other antigens still needs more research.

摘要

目的

探讨初诊CD56⁺急性髓系白血病（AML）患者的免疫表型特征。

方法

结合细胞形态学，采用四色流式细胞术分析342例CD56⁺或CD56⁻AML患者的免疫表型。

结果

342例AML患者中，83例患者CD56⁺表达阳性，占24.27%，其中M1型10例，M2型45例，M3型5例，M6型6例，M5型17例。统计学分析显示，CD56⁺与CD11b⁺患者之间存在统计学差异（P<0.05），但CD56⁺与HLA-DR、CD34、CD38、CD13、CD33、CD15、CD117、CD14、CD64、CD2、CD7、CD5、CD3、CD4、CD10、CD19、CD20、CD22之间无统计学差异（P>0.05）。